AVITA Medical, Inc.

RCELNASDAQHealthcare● Active

$4.21

+$0.05(+1.20%)

Market Cap$104588609

P/E Ratio—

52W High$7.12

52W Low$3.22

Avg Volume230K

Open$4.16

Beta1.86

Overview

AVITA Medical, Inc.（RCEL）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

rcel · 股价预测 · 7 位分析师（近3月）· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 7 位华尔街分析师

Buy

7 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 7 · 买入占比: 71.4%

12 个月目标价

High

$10.00

Consensus

$8.00

+92.3% upside

Low

$6.00

Median: $8 · Last Close: $4.16

AVITA Medical, Inc.（RCEL）的分析师共识为 Buy，基于过去 3 个月内 7 位华尔街分析师的评级。RCEL 的 12 个月平均目标价为 $8.00，相对当前价 $4.16 代表 +92.3% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

Historical priceConsensus $8 (92.3%)High $10Low $6

Consensus Target

$8.00

92.3% upside

High Target

$10

140.4%

Low Target

44.2%

Current Price

$4.16

as of today

Based on analyst price targets, the RCEL stock price prediction for the next 12 months ranges from $6 to $10. The consensus RCEL price forecast of $8.00 implies 92.3% upside from the current price of $4.16.

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-10	$4.09	↓ 1.69%	$4.06	$4.12

1-day model range: $4.06–$4.12. Peak: $4.12 (-1.69%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

0%21%79%

0Buy

3Neutral

11Sell

RSI (14)49.1Neutral

MACDBEARISH

Refreshes daily from EOD close

Moving Averages · RCEL · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$4.21SELL

MA 10$4.26SELL

MA 20$4.31SELL

MA 50$4.37SELL

MA 100$4.36SELL

MA 200$0.00NEUTRAL

Current $RCEL · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$4.22SELL

EMA 10$4.26SELL

EMA 20$4.30SELL

EMA 50$4.34SELL

EMA 100$4.34SELL

EMA 200$0.00NEUTRAL

Current $RCEL · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Date	Brokerage	Action	Rating
2026-05-15	Lake Street	Upgrade ↑	Hold→Buy
2026-04-09	D. Boral Capital	Maintains	Buy→Buy
2026-04-08	D. Boral Capital	Maintains	Buy→Buy
2026-02-17	D. Boral Capital	Maintains	Buy→Buy
2026-01-26	D. Boral Capital	Maintains	Buy→Buy
2026-01-16	Lake Street	Maintains	Hold→Hold
2026-01-15	D. Boral Capital	Maintains	Buy→Buy
2025-11-20	BTIG	Upgrade ↑	Sell→Neutral
2025-11-07	D. Boral Capital	Maintains	Buy→Buy
2025-10-17	D. Boral Capital	Maintains	Buy→Buy

分析师推荐趋势

Buy ratings1 → 1

Hold ratings1 → 0↓ 1

Sell ratings0 → 0

RCEL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$82M

↓ 32.9% YoY

Revenue Next Year

$100M

↑ 21.0% YoY

EPS This Year

$-1.10

EPS Next Year

$-0.69

↓ 37.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast RCEL EPS of $-1.10 for the current fiscal year, based on estimates from 4 analysts. The RCEL revenue forecast is $82M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

RCEL 股价预测由两类独立数据源支撑：来自 7 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RCEL 的共识目标价为 $8.00（+92.3% 上行空间），分析师共识为 Buy。

RCEL 的短期预测（明日）为 $4.09（-1.69%）。

AVITA Medical, Inc. 在 NASDAQ 上市，代码 RCEL。RCEL 在 2027 年的整体展望偏积极，在覆盖分析师中约 71% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

RCEL 预测 · 8 个问题

根据 7 位华尔街分析师，RCEL 的 12 个月平均目标价为 $8.00，最高 $10.00、最低 $6.00。若有图表，中位目标价可在上方查看。相对当前价 $4.16，隐含约 +92.3% 的上行空间。

RCEL 目标价RCEL 分析师目标价RCEL 12个月目标价目标价 RCEL

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.